Video

Dr. Kearns on AEs Associated With Surgery in Prostate Cancer

James Kearns, MD, assistant professor of medicine, Levine Cancer Institute, discusses adverse events associated with surgery in patients with high-risk prostate cancer.

James Kearns, MD, assistant professor of medicine, Levine Cancer Institute, Atrium Health, discusses adverse events (AEs) associated with surgery in patients with high-risk prostate cancer.

Maintaining a patient’s quality of life (QoL) is becoming a much more important endpoint in the treatment of prostate cancer, and Kearns says this is one reason why physicians need to have a conversation with patients before deciding if surgery is the right approach for them. Because surgery is not typically nerve-sparing in high-risk patients, they are likely to develop erectile dysfunction after the procedure. Continence rates tend to be lower, although this is not certain when treating those with “bulky” high-risk disease, Kearns adds.

Physicians often compare the AEs associated with surgery versus radiation therapy to determine which treatment approach to take for these patients. Physicians should consider if surgery will impact QoL and how the procedure will impact QoL in terms of their patients’ overall survival. If survival is being prolonged at the cost of serious QoL issues, this is something patients need to understand before a decision is made.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD